GRI Stock Analysis: Buy, Sell, or Hold?
GRI - GRI Bio, Inc. Common Stock
$1.57
-0.05 (-3.09%)
▼
5d:
-14.21%
30d:
-32.03%
90d:
-34.58%
HOLD
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 13, 2026
28d
Get Alerted When GRI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called GRI this week
33% bullish • 2 bearish
33% bullish • 2 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GRI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: GRI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: GRI is currently trading at $1.57, which is considered oversold relative to its 30-day fair value range of $1.73 to $2.17.
Technical Outlook: Technically, GRI is showing sideways momentum. The price is currently testing key support at $1.97. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: GRI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $21.00 (+1237.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GRI is showing sideways momentum. The price is currently testing key support at $1.97. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: GRI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $21.00 (+1237.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.73 -
$2.17
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.1%)
- BULLISH: Trading 1237.6% below Wall St target ($21.00)
- CAUTION: 5-day price weakness (-14.2%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.73 -
$2.17
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.97
Resistance Level
$2.31
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.62
Wall Street Target
$21.00
(+1237.6%)
Share & Embed Analysis
Last updated: July 14, 2026 9:25 PM ET
Data refreshes hourly during market hours. Next update: 10:25 PM
Data refreshes hourly during market hours. Next update: 10:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 64 BUY |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 55 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 59 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 60 BUY |
|
XNCR
Xencor Inc |
STRONG BUY
12 analysts |
$28 | 58 HOLD |
